`
`CURRICULUM VITAE
`NICHOLAS S. HILL, M.D.
`
`May 2020
`
`Nicholas S. Hill, M.D.
`Professor of Medicine
`Tufts University School of Medicine
`Chief, Pulmonary & Critical Care and Sleep Division
`Pulmonary, Critical Care and Sleep Division
`Tufts Medical Center
`800 Washington St #257
`Boston, MA 02111
`Phone: 617-636-4288
`Fax: 617-636-5953
`Email: nhill@tuftsmedicalcenter.org
`EDUCATION
`Undergraduate
`Medical
`School
`
`POSTGRADUATE TRAINING
`Internship and Residencies:
`1975-1977
`Medicine
`
`
`1971, A.B Harvard College
`1975, M.D Dartmouth Medical School
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`New England Medical Center
`Tufts University School of Medicine
`Internal Medicine Boston Veterans Admin. Medical Center
`
`
`
`
`
`1977-1978
`
`Fellowships
`1978-1979
`1979-1982
`
`LICENSURE AND CERTIFICATION
`1977
`#41058
`Massachusetts
`1987
`#7167
`Rhode Island
`1975
`Diplomate
`National Board of Medical Examiners
`1978
`Diplomate
`American Board of Internal Medicine
`1983
`Diplomate
`American Board of Internal Medicine, Pulmonary Disease
`1987, renewed 2009
`American Board of Internal Medicine, Special Qualification in Critical Care
`Medicine
`
`Cardiovasc. Med. University of Massachusetts Medical Center
`Pulmonary Med. Boston University School of Medicine
`
`
`
`
`
`
`
`
`
`
`
`
`ACADEMIC APPOINTMENTS
`1982-1987
`Assistant Professor of Medicine
`1987-1994
`Associate Professor of Medicine
`1994-2002
`Professor of Medicine
`2002-2012
`Adjunct Professor of Medicine
`
`Professor of Medicine
`
`2002-present
`
`HOSPITAL APPOINTMENTS
`1982-1987
`Assistant Physician
`1987-2012
`Associate Physician
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Tufts University School of Medicine
`Medicine
`Medicine Brown University
`Medicine Brown University
`Medicine Brown Medical School Alpert
`School of Medicine
`Tufts University School of Medicine
`
`
`Medicine
`
`
`Medicine New England Medical Center
`Medicine University Medicine Foundation,
`Rhode Island Hospital
`Medicine Rhode Island Hospital
`Medicine Meeting Street Center
`Medicine Rhode Island Hospital
`Medicine Rhode Island Hospital
`Medicine Miriam Hospital
`Medicine New England Sinai Rehabilitation
`Center
`Tufts Medical Center
`Medicine
`Medicine UMass Memorial Medical Center
`
`Director, Resp. Care Unit
`1987-1996
`1996-2000 Medical Director, Pulmonary Rehab Program
`1997-1998
`Director, Medical ICU
`1998-2002
`Director, Critical Care Service
`2000-2002
`Chief, Pulmonary Division
`2003-2012 Medical Director, Outpatient Pulmonary
`Rehabilitation Program
`2002-present Chief, Pulmonary, Critical Care & Sleep Division
`2017-
`Courtesy Medical Staff
`
`
`
`
`Liquidia's Exhibit 1003
`Page 1
`
`

`

`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`OTHER CLINICAL POSITIONS
`Medical Director
`Pulmonary Rehabilitation Program, Meeting Street Center, East Providence, RI, 1996-2000
`Medical Director
`Pulmonary Rehabilitation Program, Miriam Hospital, 2000–2002
`Medical Director
`VNA of Rhode Island, 1996–2002
`Medical Director
`Respiratory Care Tufts-New England Medical Center, 2002-present
`Medical Director
`Pulmonary Rehabilitation Program, New England Sinai Hospital, Stoughton, MA, 2003-2012
`Physician
`Pulmonary Hypertension Clinic, Rhode Island Hospital, 2002-2012
`Consultant, Louise Wilcox Multidisciplinary ALS Clinic, Rhode Island Hospital, 2003-present
`Physician
`Pulmonary Hypertension Clinic, UMass Memorial Medical Center, 2017 -present
`
`HONORS AND AWARDS
`1973
`Mosby Book Award, Dartmouth Medical School
`1971
`Phi Beta Kappa
`1975
`Alpha Omega Alpha
`1984
`Career Investigator Award, NIH
`1984
`Fellowship Award, Parker B. Francis Foundation
`2002
`Citizenship Award, City of Providence, RI
`2002
`Murray Kornfeld Honor Lecture, ACCP Annual Meeting
`2003
`Phil Kittredge Memorial Lecture, AARC Annual Meeting
`2004
`Eli Lilly Distinguished Scholar in Critical Care, Chest Foundation
`2003-
`Best Doctors in America
`Present
`2005
`2003-
`Present
`2007
`2009
`2009
`2016
`2018
`
`Henry Chadwick Medal, Massachusetts Medical Society
`Best Doctors in Boston, Boston Magazine
`
`
`Parker B. Francis Speaker, ATS International Conference
`Pulmonary Hypertension Association, Award for Excellence in PAH Care
`Margaret Pfrommer Memorial Lecture, ACCP Annual Meeting
`
`Distinguished Faculty Award, Tufts University School of Medicine
`
`Walter O’Donahue Memorial Lecture-NAMDRC Annual Meeting
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`•
`
`HOSPITAL COMMITTEES
`Internship Selection Committee
`•
`New England Medical Center Hospital, 1983-1987
`Internship Selection Committee
`Rhode Island Hospital, 1987-2002
`• Animal Welfare Committee
`Rhode Island Hospital, 1990-2002
`• Ethics Committee
`Rhode Island Hospital, 1996-2002
`• General Clinical Research Center
`Tufts-New England Medical Center, 2002-2006
`Scientific Advisory Committee
`Tufts Medical Center, 2002-2006
`• Executive Committee, Department of Medicine
`Tufts Medical Center, 2002-present
`
`•
`
`
`
`Page 2 of 32
`
`
`
`
`
`
`
`
`Liquidia's Exhibit 1003
`Page 2
`
`

`

`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`OTHER MAJOR COMMITTEE ASSIGNMENTS
`• Grant Review Committees/Study Sections : American Thoracic Society, Research Grant Review Committee, 1987-1990
`• National Heart Lung & Blood Institute Lung Biology and Pathology Review Group, Aspen, CO. June 1991
`• Program Project Grant Reviewer: October 1992
`• Promotions Committee: Department of Medicine, 1995-2002
`• Chair, Lung Biology and Pathology: Ad Hoc Review Group. 1996
`• Chair, Research Committee, Dept. of Medicine : Brown Medical School, 1999-2002
`• Strategic Planning Committee: Brown Medical School, 1999-2000
`• Chair Elect: Medical Faculty Executive Committee. Brown Medical School, 1999-2000
`• Research Advisory Committee: Academic Medical Center, 1999-2002
`• Eastern Regional Cardiopulmonary Grant Review Committee:
`American Heart Association. March, Co-Chair, 1998, Chair 1999, 2000
`• Chair: Medical Faculty Executive Committee, 2000-2001
`• Chair Emeritus: Medical Faculty Executive Committee, 2001-2002
`• Ad Hoc Reviewer: Orphan Products Division, FDA/NIH, June, 2000, Dec 2002
`• Site Visitor for Review of General Clinical Research Center: Boston University, Boston, MA. July, 2000.
`• Member ARDSnet Review Committee: NIH. March 2005
`• Member, Ad Hoc Review Group, Specialized Clinical Centers of Research, Pulmonary
`Vascular Disease, NIH. March 2006
`• Member, Ad Hoc Review Group, Centers for Multicenter Trial; Pulmonary Hypertension in
`Sickle Cell Disease, NIH. April 2006
`• Clinical Research Development Committee, Tufts Medical Center, 2007-Present
`• Gilead PAH Scholar Research Program: Research Review Committee, 2008 – Present, Chair, 2014 - Present
`• Chair, NHLBI Steering Committee : PVDomics Network 2014 - Present
`• Ad Hoc Reviewer: NHLBI Review Panel on “Translational Programs in Lung Disease (PO1), Washington, DC. Nov 2015.
`• Ad Hoc Reviewer: NHLBI Vascular Interventional/Innovations and Therapeutic Advances (VITA)
`Program Review Committee. Bolger Center, Potomac, MD. Jan 2016
`• Ad Hoc Reviewer: NHLBI Program Project Review Committee, January 2017
`• Ad Hoc Reviewer: NHLBI Clinical Trials Review Committee, February 2017
`• Ad Hoc Reviewer : NHLBI Program Project Review Committee, May 2017
`• Ad Hoc Reviewer : NHLBI PPG Review Committee, May 2018
`
`CONSENSUS CONFERENCES / GUIDELINE COMMITTEES
` American College of Chest Physicians Consensus Conference.
`Mechanical Ventilation Beyond The Critical Care Unit. October, 1993
`Joint Consensus Group on Noninvasive Ventilation
`American College of Chest Physicians and National Association of Medical Directors of Respiratory
`Care Scientific Advisor
`International Consensus, ConferenceNoninvasive Positive Pressure Ventilation in Acute Respiratory Failure.
`Paris, France. April. 2000.
` Roundtable on Mechanical Ventilation :
`European Intensive Care and Emergency Medicine Society. Brussels, Belgium. March 2003.
`
`Jury Member, International Consensus Conference: On End-of-Life in the ICU. Brussels, Belgium. April 2003.
` Presenter, International Consensus Conference: On Weaning from Mechanical Ventilation, Budapest, Hungary. March 2005.
` Summarizer Conference on Respiratory Complications of Neuromuscular Disease :
`American Respiratory Care Foundation. March, 2006
` Co-Chair , Task Force on Noninvasive Ventilation Guidelines:
`American Thoracic Society (ATS) & European Respiratory Society (ERS), 2012 - 2017
`
`
`
`
`
`
`
`
`
`
`Page 3 of 32
`
`Liquidia's Exhibit 1003
`Page 3
`
`

`

`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`
`
`
`TRAINING OF STUDENTS/POST-DOCTORAL FELLOWS
`Name
`Title
`Postdoctoral Trainees
`Alec Martin-Achard MD Role of Oxidants in Lung Injury
`Peter Jederlinic, MD
`ACE Activity In Hypoxic Lungs
`Chester Mohr MD
`NIV in Neuromuscular Disease
`James Klinger MD
`ANP in Hypoxic Pulmonary Hypertension
`Anibal Arjona PhD.
`Growth Suppressive Effect of ANP
`Raymond Petit MD
`Polycythemia and Pulmonary Hypertension
`James Nakashima PhD
`ANP Receptor Modulation in Endothelial
`Cells
`NIV in Respiratory Failure
`Thomas Meyer MD
`NIV in Respiratory Failure
`Naomi Kramer MD
`CNP Responses during Hypoxia
`Richard Swift MD
`Mechanisms of Noninvasive Ventilation
`Sangeeta Mehta MD
`James McCormick MD Masks for Noninvasive Ventilation
`Mallik Karemsetty PhD Mechanisms of Pulmonary Vasoreactivity
`John Ladetto MD
`Angiogenesis in Pulmonary Hypertension
`Ioana Preston MD
`Phosphodiesterase Inhibitors In PHT
`Tim Liesching MD
`Noninvasive Ventilation for CHF
`Vinay Maheshwari MD Utilization of NPPV in Acute Care
`Kate Steiner MD
`Pulmonary Hypertension
`Aylin Ozsancek MD
`Utilization of Noninvasive Ventilation
`Ali Khodabendeh MD
`Noninvasive Ventilation
`John Brennan MD
`Pulmonary Hypertension Critical Care
`Samy Sidhom MD
`Utilization of NoninvasiveVentilation
`Imrana Qawi MD
`Sedation for Noninvasive Ventilation
`Archan Shah MD
`Pulmonary Hypertension
`Matthew Cohn MD
`Effect of Breathe Ventilation System on
`
`Work of Breathing in COPD patients
`Viola Tracy MD
`Effect of Breathe Ventilation System on
`Work of Breathing in COPD Patients
`Nadine AlNaamani, MD Phenotypes in Pulmonary Hypertension
`
`Mona Alotaibi, MD
`
`Giulia Spoletini, MD
`
`High Flow Nasal O2 During Breaks from
`NIV
`High Flow Nasal O2 During Breaks from
`NIV
`Reliability of PAWP Measurements in PH
`Felix Yu, MD
`Christopher Manley,MD Vasoreactivity in Group 2 PH
`Ana Carolina Garza,MD Vasoreactivity in Group 2 PH
`Haval Chweich, MD
`Aerogen Nebulizer for Acute Asthma
`Alia Khoja, MD
`Physiologic Response to HFNO
`Chiara Mega, MD
`Physiologic Response to HFNO
`Maureen Spring, MD
`Physiologic Response to HFNO
`Abdallah Kharnaf, MD
`Use of Wedge Pullback Oximetry
`Alham Alonaizan, MD
`Dyspnea in DNI Patients
`Lara Pisani, MD
`Dyspnea in DNI Patients
`Najia Indrees, MD
`Aerogen Nebulizer for Acute Asthma
`Faisal Al Tamimi, MD
`Balloon Pulmonary Angiography
`Abd Abdelrahman MD Wedge Catheter Pull Back
`Mayanka Tickoo MD
`Changing Use of Nasal High Flow
`Asma Tarq, MD
`Effect of HFNC on Clearbility of Sputum
`Anas Ahmed,MD
`Wedge Catheter Poll Back
`
`Page 4 of 32
`
`Dates
`
`Current Position
`
`1983-84 Practice, Geneva, SW
`1984-85 Asst Prof of Med, Cooperstown, NY
`1985-86 Practice, Cape Cod Hospital
`1988-92 Assoc Prof. Med, Brown University
`1991-94 Research Assoc, Boston Heart Fnd
`1991-92 Private Practice, Massachusetts
`1992-99 Asst. Prof. Med, Brown University
`
`1993-94 Asst. Prof. Medicine, Jefferson Univ.
`1994-95 Asst. Prof. Medicine, Brown Univ.
`1995-96 Private Practice, New Jersey
`1995-97 Prof Medicine, Univ of Toronto
`1997-98 Private Practice, Westerly. RI
`1998-00 Asst. Prof of Med Brown University
`1999-00 Private practice, Pawtucket, RI
`2000-01 Assoc. Prof of Med, TUSM
`2001-02 University
`2003-05 Asst Prof of Med, Tufts University
`2005-06 Asst Prof Med, Harvard Medical School
`2005-08 Asst Prof of Med, Cenkan, Turkey
`2006-08 Private Practice
`2006-08 Private Practice
`2008-09 Private Practice
`2009-12 Asst Prof of Med, Tufts Medical Center
`2009-11 Staff, Kaiser Permanente, CA
`2012-13 Asst Prof of Med, National Jewish Health,
`Denver, CO.
`2012-13 Private Practice Minneapolis,, MN
`
`2013-16 Asst. Prof of Med, University of
`Pennsylvania
`2013-14 PhD Student, Leeds, UK.
`
`2013-14 Pulm Critical Care Fellow, UCSD, CA.
`
`2014-16 Asst Prof of Med, Tufts Medical Center
`2013-14 Research Fellow, Tufts Medical Center
`2013-14 Research Fellow, Tufts Medical Center
`2014-16 Asst. Prof of Med, Tufts Medical Center
`2014
`Resident, George Washington
`2014
`Pulmonologist, Bologna, Italy
`2015-17 Asst. Prof of Med, Tufts Medical Center
`2015-17 Private Practice
`2015-
`Research Scholar, Tufts Medical Center
`2015
`Researcher, Univ of Bologna, Italy
`2016
`Medical Resident, Tufts Medical Center
`2016-17 Research Scholar, Tufts Medical Center
`2017-18 Research Fellow, Tufts Medical Center
`2017-18 Research Fellow, Tufts Medical Center
`2018-19 Research Fellow, Tufts Medical Center
`2018-19 Research Fellow, Tufts Medical Center
`
`Liquidia's Exhibit 1003
`Page 4
`
`

`

`
`
`
`
`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`Page 5 of 32
`
`Liquidia's Exhibit 1003
`Page 5
`
`

`

`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`Student Trainees
`Gabriel Salameh
`James Watt
`David Sciacca
`Christopher Alia
`Grace Wang
`Brian Kwong
`Kenyatta Lee
`
`
`Pulmonary Vasoconstriction in Rats
`Endothelin in Hypoxic Vasoconstriction
`Pulmonary Hypoxic Vasoconstriction
`Vasoconstrictor Responses
`Endothelin Receptors During Hypoxia
`Angiogenesis In Pulmonary Hypertension
`Northern Analysis of Brain Natriuretic
`Peptide
`Histologic Analysis of Pulmonary Arteries
`MAP Kinases in Hypoxic Pulmonary HTN
`
`
`
`
`1994-95 Medical Student, UMDMJ
`1995-96 Unknown
`1996-97 Medical Student, Tufts
`1996-98 Medical Student, NY Medical College
`1997-98 Research Assistant, Brown University
`2000-01 Medical Student Early ID Trainee
`1995-96 Medical Student, Cornell University
`
`1997-98 Undergraduate Univ. of Delaware
`2001
`Graduate/Student, Microbiology
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Stacy Harrington
`Shanta Whitaker
`
`TEACHING RESPONSIBILITIES
`
`
`
`
`
`
`University Teaching Roles
` Mammalian Physiology
` Biomed 117
`
`Section Leader
`
`
`
`Topics in Respiratory Physiology
` Biomed 209
`
`Co-director
`
`
`
`Topics in Environmental Physiology
` Biomed 219
`
`Co-director
`
`
`
`Second year Pulmonary Pathophysiology
` Biomed 281
`
`Section Leader
`
`
`
`Small Group Leader and Lecturer-Tufts University
`
`
`
`
`
`
`
`
`
`
`
`
`
` Lecturer in second year Pathophysiology
`
`
`
`
`
`
`
`
`
`
`
`
`
` Small group Leader
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Hospital Teaching Roles
`
`
`
`
`Attending Physician, Medical Intensive Care Unit, Brown
`
`
`
`
`
`Attending Physician, Pulmonary Consult Service, Brown
`
`
`
`
`
`Attending Physician, Respiratory Care Unit, Brown
`
`
`
`Attending Physician, Pulmonary Ward, Tufts Medical Center, Boston, MA.
`
`Attending Physician, Medical Intensive Care Unit, Tufts Medical Center, Boston, MA,
`
`Attending Physician, Pulmonary Consult Service, Tufts Medical Center, , Boston, MA
`
`Attending Physician, ICU at Lowell General & Saints Memorial Hospitals, Lowell, MA.
`
`PROFESSIONAL SOCIETIES
`
`
`
`
`
`American College of Chest Physicians, Fellow 1982-
`
`
`
`
`
`American Thoracic Society, Member 1982-
`
`
`
`
`
`Massachusetts Thoracic Society, Councilor, 1982-1987
`
`
`
`
`
`American Federation for Clinical Research, Member, 1982-2004
`
`
`
`
`
`New England Chapter of American College of Chest Physicians 1984-
`
`
`
`
`
`
`American Association for the Advancement of Science, 1985-1995
`
`
`
`
`
`
`American Physiological Society, Member, 1985-2002
`
`
`
`
`
`
`Rhode Island Thoracic Society, Member 1987
`
`
`
`
`
`
`Pulmonary Hypertension Association, 2004-
`
`
`
`
`
`
`American College of Chest Physicians 2005
`
`
`
`
`
`
`Society of Critical Care Medicine, 2017 -
`
`
`
`
`
`
`European Respiratory Society 2016
`
`OFFICE AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES
` American Thoracic Society
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Program Planning Committee, Assembly on Pulmonary Circulation, 1991-1993
`
`
`
`Chair-elect, 1995 Chair, 1996. Member, 2006 - 2007
`
`
`
`
`Member, Research Coordinating Committee, 1992 - 1995
`
`
`
`
`Member, Planning Committee, 2000 - 2006
`
`
`
`Chair, Nominating Committee, Pulmonary Circulation Assembly, 2002 - 2003
`
`
`
`Member, Program Review Subcommittee, 2003 - 2004
`
`
`
`Chair, Program Planning Committee, Critical Care Assembly, 2003 - 2006
`
`
`
`Member, Nominating Committee, Critical Care Assembly, 2006 - 2007
`
`
`
`Member, Steering Committee, Critical Care Assembly, 2006 - 2007
`
`
`Secretary-Treasurer 2008-9, Vice President 2009-10, President Elect, 2010 - 2011
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 1991-1994
` 1987-1989
` 1989-1994
`1987-2002
`
`
`
`
`
` 2002-
` 2002-
`
`
`
` 1987-2002
` 1987-2002
` 1987-2002
` 2002-
` 2002-
` 2002-
` 2013-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 6 of 32
`
`Liquidia's Exhibit 1003
`Page 6
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`President 2011-12, Immediate Past President, 2012 - 2013.
`
`
`Member ,Nominating Committee, 2013 - 2015
`
`
`Member , International Lung Health Committee, 2013 - 2014
`
`
`Member, Drug/Device Discovery and Development Committee, 2013 - 2017
`
`
`Secretary-Treasurer, Board of Trustees, ATS Foundation, 2015-present
`
`
`Member, Awards Committee, 2015-17
`
`
`Chair, Executive Director Search Committee 2017-2018
`
`
`Board of Trustees, ATS Foundation 2010
`
`
` American College of Chest Physicians
`
`
`Vice Chair, Home Care Network, 2001 - 2002
`
`
`Chair, Home Care Network, 2002 - 2004
`
`
`Steering Committee, Home Care Network, 2001–10
` Rhode Island Thoracic Society
`
`
`ATS National Chapter Representative, 1991 - 2000
` New England Chapter of American College of Chest Physicians
`
`
`• Vice President, 1994 - 1995
`• President, 1995 - 1996
` Pulmonary Hypertension Association 2004
`
`
`Member, Scientific Leadership Committee, 2004 - 2012
`
`MAJOR RESEARCH INTERESTS
` Pulmonary Vascular Biology
`My main focus has been on the regulation of pulmonary vascular tone using hypoxia as a model. I have devoted considerable attention
`to the role of natriuretic peptides in ameliorating hypoxic pulmonary vasoconstriction and remodeling, and more recent interests have
`been in the role of angiogenic factors in hypoxic pulmonary hypertension, the role of serotonins in modulating pulmonary
`vasoreactivity, retinoic acid and the pathogenesis of PH, and signal transduction pathways including lipoxygenases and endothelin.
`More recently we are looking at cell permeable peptides as possible physiologic and therapeutic tools.
` Clinical Pulmonary Hypertension
`I established a Pulmonary Hypertension Center at Rhode Island Hospital and Tufts Medical Center and get referrals from all over
`Southern New England. My group has participated in many multicenter trials to evaluate the role of both intravenous and
`subcutaneous prostacyclins and more recently oral endothelin antagonists and combination therapy. We have also published many
`studies on therapeutic approaches in various forms of pulmonary hypertension, and continue to be interested in contributing to
`advances in therapy and suggesting new possible therapeutic approaches.
` Noninvasive Ventilation
`A major interest in clinical research has been to evaluate ways of delivering and testing the efficacy of noninvasive ventilation; the
`provision of mechanical ventilatory assistance without requiring an invasive airway. My group has performed a number of controlled
`trials dealing with these issues, and continues to examine new applications, improved techniques, and ethical aspects of noninvasive
`ventilation. Our most recent thrust has been to explore ways of enhancing the utilization of noninvasive ventilation in critical care
`and to understand the effect of noninvasive ventilation on sleep in the ICU. We have also initiated studies on nasal high flow therapy,
`another noninvasive approach to providing respiratory assistance, examining physiologic effects in COPD patients as well as use
`during breaks from bi-level noninvasive ventilation.
` High Flow Nasal Therapy
`The delivery of heated, humidified, oxygenated gas via soft cannulas intranasally is a newer technique for oxygen delivery and
`ventilatory assistance. We are involved in studies to understand physiologic effects, appropriate indications, outcomes and
`epidemiology of use
`
`
`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`
`
`Page 7 of 32
`
`Liquidia's Exhibit 1003
`Page 7
`
`

`

`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`
`RESEARCH SUPPORT
`GRANT AWARD/ FUNDING AGENCY/Private Foundations/Industry Awards
`• CLINICAL INVESTIGATOR AWARD, NHLBI
`Principal Investigator
`• GRANT-IN-AID AMERICAN THORACIC SOCIETY
`Principal Investigator
`• PARKER B. FRANCIS FOUNDATION FELLOWSHIP
`Principal Investigator
`• SHERMAN-WELCH FOUNDATION AWARD
`Massachusetts Thoracic Society
`Principal Investigator
`• TRAVENOL, INC
`Grant for Study of Negative Pressure Ventilation in COPD
`Co-Investigator
`• GRANT-IN-AID, RHODE ISLAND HEART ASSOCIATION
`Principal Investigator
`• RESPIRONICS, INC.
`Grant for Study of Nasal Ventilation in COPD
`Principal Investigator
`• GRANT-IN-AID, RHODE ISLAND HEART ASSOCIATION
`Principal Investigator
`• RESPIRONICS, INC.
`Grant for Study of Nasal Ventilation in Neuromuscular Disease
`Principal Investigator
`• BURROUGHS-WELLCOME, INC.
`Multicenter Trial Of Prostacyclin Infusion in Primary Pulmonary Hypertension
`Principal Investigator
`• RESPIRONICS, INC
`Grant for Study of Nasal Ventilation
`Principal Investigator
`• LIFECARE, INC.
`Grant for Study of Negative Pressure Ventilator
`Principal Investigator
`• RHODE ISLAND HEART ASSOCIATION - GRANT-IN-AID,
`Principal Investigator
`
`• RESPIRONICS, INC.
`Comparison of Bipap vs CPAP In Management of Acute Pulmonary Edema
`Principal Investigator
`• PURITAN-BENNETT, INC
`Grant for Evaluation Of 335 Bi-level Positive Airway Pressure Ventilation
`Principal Investigator
`• RESPIRONICS, INC
`Evaluation of Exhalation Valves for Bilevel Positive Airway Pressure Ventilation
`Principal Investigator
`• MILES LABORATORY
`Phase III Trial of Norasept (Anti-TNF Antibody) for the Therapy of Sepsis.
`Principal Investigator
`• RESPIRONICS, INC
`Evaluation of Oronasal vs Nasal Masks for Administration of Noninvasive Ventilation
`Principal Investigator
`• GLAXO-WELLCOME, INC.
`Randomized Trial of Intravenous Flolan for Patients with PH due to Scleroderma
`
`
`
`
`Page 8 of 32
`
`
`
`
`
`$ AMOUNT
`• $50,000
`
`• $17,500
`
`• $25,000
`
`• $5,000
`
`YEAR(S)
`• 1983-1988
`
`• 1983-1985
`
`• 1983-1987
`
`• 1983-1985
`
`• $25,000
`
`• 1984-1986
`
`• $20,000
`
`• $18,000
`
`• 1988-1989
`
`• 1988-1989
`
`• $20,000
`
`• 1990-1991
`
`• $5,000
`
`• 1990
`
`• $20,000
`
`• 1991-1994
`
`• $8,000
`
`• 1992
`
`• $16,000
`
`• 1993
`
`• $25,000
`
`• $18,300
`
`• 1993-1995
`
`• 1994-1995
`
`• $4,000
`
`• 1995
`
`• $14,000
`
`• 1995-1996
`
`• $20,000
`
`• 1996-1997
`
`• $5,000
`
`• 1996-1997
`
`• $20,000/pt.
`
`• 1997-1998
`
`Liquidia's Exhibit 1003
`Page 8
`
`

`

`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`• RESPIRONICS, INC.
`Evaluation of the Vision Proportional Assist Ventilator
`Principal Investigator
`• RHODE ISLAND HEART ASSOCIATION - GRANT-IN-AID,
`Modulation of Pulmonary Hypertension by Natriuretic Peptides
`Principal Investigator
`• RESMED, INC.
`Randomized Trial of Noninvasive Ventilation to Facilitate Extubation of Patients with
`Respiratory Failure
`• UNITED THERAPEUTICS INC.
`Randomized Trial of Subcutaneous UT-15 to Treat Patients with Severe Pulmonary
`Hypertension
`• RESMED, INC.
`Randomized Trial of NPPV after Hypercapnic Respiratory Failure in COPD.
`Principal Investigator
`• SUNTORY, INC.
`Phase II Multicenter Trial of Alpha-hANP Infusion in ARDS.
`Principal Investigator
`• ICOS PHARMACEUTICALS/TEXAS BIOCHEMICAL
`Randomized Controlled Trial of Sitaxsentan in the Therapy of Severe PH
`• RESPIRONICS, INC.
`Trial of the Total Face Mask for Noninvasive Ventilation
`• PFIZER, INC.
`Randomized Trial of the Phosphodiesterase Inhibitor, Sildendafil in PAH
`• ACTELION, INC.
`Transition from Prostacyclin Infusion to Oral Bosentan (Investigator Initiated)
`• MYOGEN, INC.
`Randomized Trial of Ambrisentan to Treat Patients with Pulmonary Arterial Hypertension
`• PFIZER, INC.
`Randomized Trial of the Phosphodiesterase Inhibitor, Sildenafil, Added to Intravenous
`Epoprostenol in Patients with Pulmonary Arterial Hypertension.
`• UNITED THERAPEUTICS, INC.
`Transition from IV Epoprostenol to Sc Treprostinil (Investigator Initiated)
`• ELI LILLY.
`Distinguished Scholar in Critical Care Medicine Chest Foundation, Enhancing the Utilization of
`Noninvasive Positive Pressure Ventilation.
`• ENCYSIVE, INC.
`Open-Label Trial of Sitaxsentan In The Therapy Of Severe Pulmonary Hypertension.
`• RESMED, INC.
`Investigation of Inspiratory Time Limits for Enhancing Patient-Ventilator Synchrony During
`Noninvasive Ventilation
`• UNITED THERAPEUTICS, INC.
`Trial Of Ropivacaine, A Local Anesthetic, In Controlling Site Pain during Sc Treprostinil
`Infusion.
`• SUNOL, INC.SAFETY
`Pharmacokinetics and Physiological Effects Of Ch36 In Patients with Acute Lung Injury
`• ASTRA-ZENCA, INC.
`Efficacy and Safety of Quetiapine in Medical Intensive Care Unit Patients with Delirium: a
`Randomized Study
`• ICOS PHARAMACEUTICALS, INC.
`Randomized, Controlled Trial of Tadalafil to Treat Pulmonary Arterial Hypertension.
`• RESPIRONICS, INC.
`Enhancement of the Utilization of Noninvasive Positive Pressure Ventilation Multicenter Trial.
`• COTHERIX, INC.
`Addition of Inhaled Iloprost to Sildenafil In Pulmonary Arterial Hypertension Multicenter Trial
`
`
`
`
`Page 9 of 32
`
`• $62,500
`
`• 1997-1998
`
`• $30,000
`
`• 1997-1999
`
`• $40,000
`
`• 1998-1999
`
`• $15,000/pt.
`
`• 1998-1999
`
`• $40,000
`
`• 2000-
`
`• $45,000
`
`• 2000-
`
`• $20,000/pt.
`
`• 2001-2002
`
`• $10,000
`
`• 2002-2003
`
`• $17,000/pt.
`
`• 2003
`
`• $35,000/yr.
`
`• 2003-2005
`
`• $15,000/pt.
`
`• 2003-2005
`
`• $17,000/pt.
`
`• 2003–2005
`
`• $40,000
`
`• 2003-2005
`
`• $50,000/yr.
`
`• 2003-2006
`
`• $17,000/pt.
`
`• 2004-2006
`
`• $40,000
`
`• 2004-2005
`
`• 2,000 /pt.
`
`• 2005
`
`• 8000/pt.
`
`• 2005
`
`• $5,000/pt.
`
`• 2005-2006
`
`• $8,000/pt.
`
`• 2005-2006
`
`• $333,000/yr.
`
`• 2005-2008
`
`• $8,000/pt.
`
`• 2006-2007
`
`Liquidia's Exhibit 1003
`Page 9
`
`

`

`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`• ACTELION, INC.
`Addition of Bosentan to Sildenafil In Pulmonary Arterial Hypertension, Multicenter Trial
`• UNITED THERAPEUTICS, INC.
`Evaluation of Oral Treprostinil In Pulmonary Arterial Hypertension Multicenter Trial
`• LUNG RX, INC.
`Addition of inhaled Treprostinil to Sildenafil or Bosentan In Pulmonary Arterial Hypertension
`Multicenter Trial.
`• EPIX PHARMACEUTICALS
`Effect of Serotonin B2 Receptor Blockade On Pulmonary Hypertension in COPD.
`• GILEAD SCIENCES, INC
`Ambrisentan to Treat Patients with WHO Groups 1,3 and 4 PAH ARIES 3.
`• UNITED THERAPEUTICS
`Long-term effects of inhaled treprostinil
`• RESPIRONICS GRANT
`Utilization of Noninvasive Ventilation in Acute Care. The major goal of this multicenter project
`is to evaluate the utilization of noninvasive ventilation in acute respiratory care in different
`hospitals.
`• ACTELION, INC.
`Study to assess the safety and tolerability of ACT-064992 in patients with symptomatic PAH.
`• UNITED THERAPEUTICS
`Evaluation of oral treprostinil effect on exercise capacity
`• UNITED THERAPEUTICS
`A post-marketing observational study to assess respiratory tract adverse events in pulmonary
`arterial hypertension patients treated with Tyvaso (treprostinil) inhalation solution
`• ACTELION, INC. (REVEAL)
`Registry of pulmonary hypertension patients
`• UNITED THERAPEUTICS
`An open-label extension trial of UT-15C SR in subjects with Pulmonary Arterial Hypertension
`• BAYER
`Randomized controlled trial to evaluate efficacy and safety of oral BAY 63-2521 in patients
`with PAH (2 studies – blinded and extension)
`• HOSPIRA
`Use of dexmetatomidine as sedative agent during non-invasive ventilation
`• GILEAD SCIENCES, INC
`Randomized controlled study of Cicletanine in subjects with Pulmonary Arterial Hypertension
`• GILEAD SCIENCES, INC. (AMBITION)
`Assesses the effect of an upfront combination of Tadalafil and Ambrisentan compared to each
`drug alone in patients with pulmonary arterial.
`• GeNO LLC
`Evaluates new way to deliver inhaled nitric oxide and assesses response in patients with
`pulmonary hypertension
`• RESPIRONICS
`High intensity non-invasive positive pressure ventilation (NPPV) for stable hypercapnic COPD
`patients
`• UNITED THERAPEUTICS, INC.
`A post-marketing observational study to assess respiratory tract adverse events in pulmonary
`arterial hypertension patients treated with Tyvaso (treprostinil) inhalation solution.
`• PHAROS
`Examines natural history of scleroderma in registry centered at Georgetown Medical Center
`• ACTELION, INC.
`Long-term effect of combination therapy with bosentan and sildenafil (Compass II)
`• CHEST FOUNDATION-RESPIRONICS
`Enhancing utilization of non-invasive ventilation in critical care
`• ACTELION, INC.
`Study to assess the safety and tolerabllity of ACT-064992 in patients with symptomatic PAH.
`
`
`
`
`Page 10 of 32
`
`• $8,000/pt.
`
`• 2006-2007
`
`• $8,000/pt.
`
`• 2006-2007
`
`• $8,000/pt.
`
`• 2006-2007
`
`• $8,000/pt.
`
`• 2006-2007
`
`• $8,000/pt.
`
`• 2006-2007
`
`• $10,000/pt.
`
`• 2007-2008
`
`•
`
`• 2007-2013
`
`• $10,000/pt.
`
`• 2008-2009
`
`• $6,000/pt.
`
`• 2008-2010
`
`• $4,000/pt.
`
`• 2008-2010
`
`• $3,000/pt.
`
`• 2008-
`
`• $4,000/pt.
`
`• 2009-2010
`
`• $8,000/pt.
`
`• 2009-2012
`
`• $3,000/pt.
`
`• 2009-
`
`• $8,000/pt.
`
`• 2009-2012
`
`• $14,000/pt.
`
`• 2010-2014
`
`• $3,000/pt.
`
`• 2010
`
`• $3,000/pt.
`
`• 2010-2011
`
`• $3,000/pt.
`
`• 2010-2014
`
`• $2,000/pt.
`
`• 2010-2015
`
`• $10,000/pt.
`
`• 2010-2016
`
`• 1,000,000
`
`• 2010-2016
`
`• $14,000/pt.
`
`• 2010-2016
`
`Liquidia's Exhibit 1003
`Page 10
`
`

`

`NICHOLAS S. HILL, M.D.
`CURRICULUM VITAE 2020
`
`• GENZYME PHARMACEUTICALS
`Evaluation of neutral endopeptidase inhibitor + nitric oxide in rates with pulmonary
`hypertension induced by monocrotalins
`• BREATHE TECHNOLOGIES, INC.
`Effect of Noninvasive Open Ventilation (NICU) on Work of Breathing in COPD patients.
`• FISHER PAYKEL HEALTH INC.
`Role of high flow nasal O2 during breaks from NIV
`• FISHER PAYKEL HEALTH INC.
`Physiologic Effects of High Flow Nasal H20 in COPD
`• GILEAD SCIENCES, INC.
`A Phase 2 randomized, double-blind, placebo-controlled multi-center study to assess the
`efficacy and safety of GS-6624 (Simtuzumab) in subjects with idiopathic pulmonary fibrosis
`• UNITED THERAPEUTICS, INC.
`A phase III, international, multi-center, randomized, double-blind, placebo-controlled, clinical
`worsening study of UT-15C in subjects with pulmonary arterial hypertension receiving
`background oral monotherapy
`• ACTELION, INC. (SERAPHIN)
`Study to assess the safety and tolerabllity of ACT-064992 in patients with symptomatic
`pulmonary arterial hypertension (blinded and open label)
`• REATA PHARMACEUTICALS
`A dose-ranging study of the efficacy and safety of bardoxolone methyl in patients with PAH.
`• AERODYNE, INC
`Aerogen Nebulizer For Treatment Of Acute Asthma
`• ACTELION, INC.
`Phase 3b study of macitentan in patients with pulmonary arterial hypertension to
`psychometrically validate the PAH-SYMPACT instrument.
`• UNITED THERAPEUTICS INC.
`A multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the safety and
`efficacy of inhaled Treprostinil in subjects with pu